Can-Fite Biopharma Ltd

Stage 4 · Declining · week 6

As of Oct 22, 2026, Can-Fite Biopharma is in Stage 4, the downtrend phase, now in week 6 (since Sep 11, 2026). It closed at $1.83, 81.7% below its 52-week high and below its 200-day average, which is falling.

$1.83

-3.15% today

$5.5M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CANF early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 28w

S4 22w

S4 65w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 2w → S4 28w → S1 7w → S4 2w → S1 2w → S2 11w → S3 6w → S4 22w → S1 3w → S4 65w → S1 4w → S4 2w → S1 3w → S4 6w current

Total tracked: 165 weeks across 14 stage runs.

CANF among Biotechnology481st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…481	CANFCan-Fite Biopharma Ltd	Stage 4 · wk 6	10	−15.3%

vs 52W High

-81.7%

$1.76 lo$10.00 hi

81.7% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 6

1w13w26w

Week 6, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-44.3%

200 DMA: $3.29 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.04x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-15.3%

-42.6%

-37.1%

YTD

-58.4%

-82.1%

Scan Membership

Breakout Watch

Latest: 2024-06-10

4 appearances in last 60 days. First seen: 2020-08-27.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 6 · Vol 0.04x

2026-10-21S4

Wk 6 · Vol 0.02x

2026-10-20S4

Wk 6 · Vol 0.04x

2026-10-19S4

Wk 6 · Vol 0.03x

2026-10-16S4

Wk 6 · Vol 0.06x

2026-10-15S4

Wk 5 · Vol 0.06x

2026-10-14S4

Wk 5 · Vol 0.03x

2026-10-13S4

Wk 5 · Vol 0.04x

2026-10-12S4

Wk 5 · Vol 0.05x

2026-10-09S4

Wk 5 · Vol 0.07x

2026-10-08S4

Wk 4 · Vol 0.15x

2026-10-07S4

Wk 4 · Vol 0.10x

Moving averages & range

50 DMA

$2.47

200 DMA

$3.29

52W High

$10.00

52W Low

$1.76

5D Low

$1.76

Resistance levels (recent highs)

20d High

$2.23

60d High

$3.58

120d High

$4.63

250d High

$9.40

Next resistance

+21.9%

to 20d High

ROE

-211.4%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.8

Can-Fite Biopharma: quick answers

What stage is Can-Fite Biopharma in?

As of Oct 22, 2026, Can-Fite Biopharma (CANF) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 11, 2026 and is in week 6. What the four stages mean

Is Can-Fite Biopharma in an uptrend?

No. Can-Fite Biopharma is in a Stage 4 downtrend. It trades 44.3% below its 200-day average, which is falling.

How far is Can-Fite Biopharma from its 52-week high?

Can-Fite Biopharma closed at $1.83 on Oct 22, 2026, 81.7% below its 52-week high of $10.00. Its 52-week low is $1.76.

How has Can-Fite Biopharma performed over the past year?

As of Oct 22, 2026, Can-Fite Biopharma is down 82.1% over the past year and down 58.4% so far in 2026.

Which sector and industry is Can-Fite Biopharma in?

Can-Fite Biopharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.